Keeping the HOP(A) Live—Annual Conference Research Highlights

JHOP - March 2023 Vol 13 Special Feature - Editorial
By Mark L. Zangardi, PharmD, MS, BCOP; Sara Kim, PharmD, BCOP
Dr Zangardi is the HOPA Abstract Review Subcommittee Chair, 2022-2023, and Pharmacy Coordinator, Oncology Precision Medicine, OhioHealth Pharmacy Services, Columbus, OH. Dr Kim is the HOPA Abstract Review Subcommittee Vice Chair, 2022-2023, and Senior Oncology Clinical Pharmacy Specialist, Zuckerberg Cancer Center, Northwell Health Cancer Institute, Lake Success, NY.
Download PDF

We are pleased to welcome you to this special issue of the Journal of Hematology Oncology Pharmacy (JHOP), the official publication of the Hematology/Oncology Pharmacy Association (HOPA). This special issue is the Third Annual Issue of HOPA Abstracts, 2023, showcasing abstracts presented at the 19th HOPA Annual Conference, March 29 through April 1, 2023, in Phoenix, AZ. The abstracts published in this issue exhibit the valuable, impactful research submitted by HOPA members and nonmembers, including hematology/oncology pharmacists, other healthcare providers, and scientists from across the country and around the world.

The Annual Conference Abstract Review Subcommittee of HOPA, consisting of HOPA member volunteers, establishes and maintains policies and procedures related to research abstract submission criteria. The subcommittee is responsible for reviewing completed, late-breaking, and trainee research. Submitted research covers a wide range of clinical/translational and practice management topics, including benign or malignant hematology, solid tumors, blood and marrow transplant/cellular therapy, supportive care, medication safety, pharmacist roles, quality improvement, and the value of cancer care, among others. In accordance with its policies and procedures, the Annual Conference Abstract Review Subcommittee selects abstracts to be presented as posters at the HOPA Annual Conference each year, including those honored as platform or Trainee Top 10 presentations. At the HOPA Annual Conference, subcommittee members also serve as trainee poster evaluators, Trainee Top 10 presentation judges, and moderators of platform presentations.

This year, 45 completed and late-breaking research abstracts were submitted for consideration, all of which were peer reviewed by a committee of subject matter experts representing various hematology/oncology subspecialties and practice areas. Initially, each abstract is reviewed and scored by select members of the Abstract Review Subcommittee, followed by discussion among the full subcommittee. All abstracts are thoroughly critiqued regarding scientific merit and meaningful application of the research to HOPA members and attendees of the HOPA Annual Conference. Abstracts selected as late-breaking research must also demonstrate a significant impact on hematology/oncology pharmacy practice that warrants more immediate review and dissemination.

This year’s platform presentations feature research on real-world clinical outcomes with Bruton tyrosine kinase inhibitors, the impact of clinical pharmacist–initiated tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia, knowledge gaps in cancer therapy–related cardiovascular toxicities and related drug interactions, and optimization of corticosteroid use for immune-related adverse events.

HOPA members and contributors are leaders in hematology/oncology pharmacy practice and integral members of the healthcare community, optimizing cancer care for the patients we serve. Research presented at the HOPA Annual Conference demonstrates HOPA’s commitment to education, advancement of professional practice, collaboration, innovation, and quality. We hope you learn from and are inspired by the high-quality abstracts featured in this issue of JHOP. We look forward to abstract submissions from YOU in the future!

Related Items
New Year, New HOP(A): Return of the Annual Conference Research Abstracts
JHOP - March 2024 Vol 14 Special Feature published on March 21, 2024 in Editorial
Are We Ready for Same-Day Pegfilgrastim and Chemotherapy?
JHOP - October 2023 Vol 13, No 5 published on October 16, 2023 in Editorial
JHOP Editorial Board Member, Readers, and Author Interact - Optimizing the Administration of Daratumumab
JHOP - June 2023 Vol 13, No 3 published on June 21, 2023 in Editorial, Letters to the Editor
JHOP Editorial Board Member, Readers, and Author Interact - Comment on Kye et al (April 2023), Authors’ Response
JHOP - June 2023 Vol 13, No 3 published on June 21, 2023 in Letters to the Editor, Editorial
Optimal Sequencing of Cancer Treatments an Increasingly Important Question
JHOP - August 2022 Vol 12, No 4 published on August 19, 2022 in Editorial
Adoption of Biosimilars—Why the Delay?
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Editorial, Biosimilars
Protecting Patients with Cancer During the COVID-19 Pandemic
Robert Mancini, PharmD, BCOP, FHOPA, Timothy G. Tyler, PharmD, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 published on April 26, 2022 in Editorial, COVID-19
HOP(A) Springs Eternal
Bryna Delman Ewachiw, PharmD, BCOP, Mark L. Zangardi, PharmD, BCOP
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in Editorial, HOPA Abstracts
Dosing Chemotherapy in Obese Patients, Still Not Answered
Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
JHOP - December 2021 Vol 11, No 6 published on December 16, 2021 in Editorial, Chemotherapy, Obesity
Urine Alkalinization and Methotrexate Clearance: Are These Key to Safe Administration of High-Dose Methotrexate?
Joseph Bubalo, PharmD, BCPS, BCOP
JHOP - October 2021 Vol 11, No 5 published on October 28, 2021 in Editorial, Chemotherapy, Oncology Pharmacy Protocols
© Amplity Health. All rights reserved.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: